Journal article

Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy

Emily Gwyer Findlay, Andrew J Currie, Ailiang Zhang, Jana Ovciarikova, Lisa Young, Holly Stevens, Brian J McHugh, Marta Canel, Mohini Gray, Simon WF Milling, John DM Campbell, John Savill, Alan Serrels, Donald J Davidson

ONCOIMMUNOLOGY | TAYLOR & FRANCIS INC | Published : 2019

Abstract

Immunization of patients with autologous, ex vivo matured dendritic cell (DC) preparations, in order to prime antitumor T-cell responses, is the focus of intense research. Despite progress and approval of clinical approaches, significant enhancement of these personalized immunotherapies is urgently needed to improve efficacy. We show that immunotherapeutic murine and human DC, generated in the presence of the antimicrobial host defense peptide LL-37, have dramatically enhanced expansion and differentiation of cells with key features of the critical CD103+/CD141+ DC subsets, including enhanced cross-presentation and co-stimulatory capacity, and upregulation of CCR7 with improved migratory cap..

View full abstract